Just–Evotec Biologics opens 130,000 sq ft Redmond J.POD to manufacture COVID‑19 antibody therapeutics for U.S. Defense

Just–Evotec Biologics opened a 130,000 sq ft J.POD drug manufacturing facility in Redmond, Washington that uses continuous, autonomous bioprocessing to design, develop and produce antibody therapeutics more efficiently and at lower cost. The plant will manufacture antibodies for the U.S. Department of Defense to potentially treat COVID-19 and supports both small- and large-scale production for biotech customers globally.

JJames Thomas JJust Biotherapeutics